scholarly journals Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival

2020 ◽  
Vol 122 (6) ◽  
pp. 801-811 ◽  
Author(s):  
Afroditi Nanou ◽  
M. Craig Miller ◽  
Leonie L. Zeune ◽  
Sanne de Wit ◽  
Cornelis J. A. Punt ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Extracellular Vesicles ◽  
Metastatic Cancer

scholarly journals Leukocyte-Derived Extracellular Vesicles in Blood with and without EpCAM Enrichment

Cells ◽  
2019 ◽  
Vol 8 (8) ◽  
pp. 937 ◽  
Author(s):  
Afroditi Nanou ◽  
Leonie L. Zeune ◽  
Leon W.M.M. Terstappen
Keyword(s):  
Cancer Patients ◽  
Extracellular Vesicles ◽  
Metastatic Cancer ◽  
Image Data ◽  
Data Sets ◽  
Healthy Individuals ◽  
Large Tumor ◽  
Microscopy Imaging ◽  
Lung Cancer Patients ◽  
Cluster Of Differentiation

Large tumor-derived Extracellular Vesicles (tdEVs) detected in blood of metastatic prostate, breast, colorectal, and non-small cell lung cancer patients after enrichment for Epithelial Cell Adhesion Molecule (EpCAM) expression and labeling with 4′,6-diamidino-2-phenylindole (DAPI), phycoerythrin-conjugated antibodies against Cytokeratins (CK-PE), and allophycocyanin-conjugated antibody against the cluster of differentiation 45 (CD45-APC), are negatively associated with the overall survival of patients. Here, we investigated whether, similarly to tdEVs, leukocyte-derived EVs (ldEVs) could also be detected in EpCAM-enriched blood. Presence of ldEVs and leukocytes in image data sets of EpCAM-enriched samples of 25 healthy individuals and 75 metastatic cancer patients was evaluated using the ACCEPT software. Large ldEVs could indeed be detected, but in contrast to the 20-fold higher frequency of tdEVs as compared to Circulating Tumor Cells (CTCs), ldEVs were present in a 5-fold lower frequency as compared to leukocytes. To evaluate whether these ldEVs pre-exist in the blood or are formed during the CellSearch procedure, the blood of healthy individuals without EpCAM enrichment was labelled with the nuclear dye Hoechst and fluorescently tagged monoclonal antibodies recognizing the leukocyte-specific CD45, platelet-specific CD61, and red blood cell-specific CD235a. Fluorescence microscopy imaging using a similar setup as the CellSearch was performed and demonstrated the presence of a similar population of ldEVs present at a 3-fold lower frequency as compared to leukocytes.

scholarly journals Lymphocyte-C-Reactive Protein Ratio with Calf Circumference Could Better Predict Survival of Patients with Non-Metastatic Cancer

2022 ◽  
Author(s):  
Han-Ping Shi ◽  
Xiao-Yue Liu ◽  
Xi Zhang ◽  
Qi Zhang ◽  
Guo-Tian Ruan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Predictive Value ◽  
Inflammatory Responses ◽  
Inflammatory Marker ◽  
Metastatic Cancer ◽  
Calf Circumference ◽  
C Reactive Protein ◽  
Protein Ratio ◽  
Reactive Protein

Abstract Background Systemic inflammatory responses caused by tumor cells play an important role in the occurrence and development of tumors. Most of these responses are accompanied by a decrease in muscle mass. The aim of this study was to identify biomarkers that most accurately predict prognoses in patients with non-metastatic cancer and to evaluate their clinical significance when combined with muscle markers. Methods This study retrospectively evaluated 2,797 cancer patients diagnosed with cancer at TNM stages I, II, and III. Lymphocyte-C-reactive protein ratio (LCR) in conjunction with calf circumference (CC) were used (or chosed) after evaluating the predictive value of 13 inflammatory marker combinations and five anthropometric indicators for patient outcomes using the C-index. The Kaplan-Meier method and Cox’s proportional hazards regression modeling were used to analyze the individual and combined effects of these two potential biomarkers on overall survival. Results This study enrolled 1,604 men (57.3%) and 1,193 women (42.7%) with a mean age of 58.75 years. Among the 13 inflammatory nutritional indicators, the LCR was the most accurate predictor of prognoses in patients with non-metastatic cancer. The optimal threshold for the LCR was 2,500. After multifactorial adjustment, we found that low LCR had an adverse effect on overall survival (hazard ratio [HR]: 2.50; 95% confidence interval [CI]: 2.17, 2.88; P<0.001). Low LCR combined with low CC was also shown to be an independent risk factor for poor overall survival (HR: 2.26; 95% CI: 1.80, 2.83; P<0.001). In non-metastatic cancer patients of different ages, stages, surgery history, and tumor types (for example, upper gastrointestinal cancer, colorectal cancer, lung cancer), patients with a low LCR combined with a low CC had statistically significantly reduced overall survival. Compared with LCR or CC alone, the combination of the two had greater prognostic value for patients with non-metastatic cancer. Conclusions The LCR can be implemented as a useful biomarker to predict prognoses in patients with non-metastatic cancer, its predictive value is superior to the other evaluated indicators of inflammation. CC is the best anthropometric indicator of muscle loss in patients with non-metastatic cancer. The combination of LCR and CC can better predict the prognosis of patients with non-metastatic cancer, and can provide important information for clinicians to formulate diagnosis and treatment plans.

scholarly journals Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Rokas Račkauskas ◽  
Augustinas Baušys ◽  
Martynas Lukšta ◽  
Jonas Jurgaitis ◽  
Marius Paškonis ◽  
...  
Keyword(s):  
Overall Survival ◽  
Peritoneal Carcinomatosis ◽  
Cancer Patients ◽  
Postoperative Morbidity ◽  
Metastatic Cancer ◽  
Objective Assessment ◽  
Peritoneal Metastases ◽  
Initial Experience ◽  
Invasive Approach ◽  
The Baltic

Abstract Background Peritoneal malignancies include primary and metastatic cancer of the peritoneal cavity. The most common origin for peritoneal metastasis is ovarian, gastric, and colorectal cancers. Irrespective of the origin, peritoneal metastases represent the advanced disease and are associated with poor long-term outcomes. The minimally invasive approach of pressurized intraperitoneal aerosol chemotherapy (PIPAC) allows repeated applications and objective assessment of tumor response by comparing histological samples. This study aimed to investigate the initial experience with PIPAC in the Baltic region. Methods All patients who underwent PIPAC at Vilnius University Hospital Santaros Klinikos between 2015 and 2020 were included in this retrospective study. The primary outcome of the study was overall survival (OS) in patients with peritoneal carcinomatosis treated by PIPAC. The secondary outcomes included postoperative morbidity; peritoneal carcinomatosis index (PCI) and ascites reduction after treatment by PIPAC. Results In total, 15 patients underwent 34 PIPAC procedures. PIPAC-related intraoperative and postoperative morbidity occurred in 3 (8.8%) of 34 procedures. Following PIPAC, the median PCI decreased from 8 (4; 15) to 5 (1; 16) in GC patients, although, the difference failed for significance, p = 0.581. In OC patients, PCI after PIPAC remained stable. Median overall survival after PIPAC procedure was 25 (95% CI 5–44) months. Ovarian cancer patients (22; 95% CI 12–44 months) had significantly higher OS, compared to gastric cancer patients (8; 95% CI 4–16 months), p = 0.018. Conclusions PIPAC is safe and feasible for patients with gastric and ovarian cancers peritoneal metastases.

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

274 High-dose medroxyprogesterone acetate (MPA) in metastatic cancer patients

1983 ◽  
Vol 19 ◽  
pp. 91
Author(s):  
P. Schmidt-Rhode ◽  
G. Sturm ◽  
K.-D. Schulz ◽  
H.J. Künzig ◽  
M. Wunsch
Keyword(s):  
Cancer Patients ◽  
Medroxyprogesterone Acetate ◽  
Metastatic Cancer ◽  
High Dose

scholarly journals Combination of the G-8 Screening Tool and Hand-Grip Strength to Predict Long-Term Overall Survival in Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3363
Author(s):  
Kristian Kirkelund Bentsen ◽  
Olfred Hansen ◽  
Jesper Ryg ◽  
Ann-Kristine Weber Giger ◽  
Stefan Starup Jeppesen
Keyword(s):  
Overall Survival ◽  
Grip Strength ◽  
Cancer Patients ◽  
Stereotactic Body Radiotherapy ◽  
Statistical Significance ◽  
Multivariable Analysis ◽  
Hand Grip Strength ◽  
Physical Test ◽  
Hand Grip

The Geriatric 8 (G-8) is a known predictor of overall survival (OS) in older cancer patients, but is mainly based on nutritional aspects. This study aimed to assess if the G-8 combined with a hand-grip strength test (HGST) in patients with NSCLC treated with stereotactic body radiotherapy can predict long-term OS better than the G-8 alone. A total of 46 SBRT-treated patients with NSCLC of stage T1-T2N0M0 were included. Patients were divided into three groups: fit (normal G-8 and HGST), vulnerable (abnormal G-8 or HGST), or frail (abnormal G-8 and HGST). Statistically significant differences were found in 4-year OS between the fit, vulnerable, and frail groups (70% vs. 46% vs. 25%, p = 0.04), as well as between the normal and abnormal G-8 groups (69% vs. 39%, p = 0.02). In a multivariable analysis of OS, being vulnerable with a hazard ratio (HR) of 2.03 or frail with an HR of 3.80 indicated poorer OS, but this did not reach statistical significance. This study suggests that there might be a benefit of adding a physical test to the G-8 for more precisely predicting overall survival in SBRT-treated patients with localized NSCLC. However, this should be confirmed in a larger study population.

Sign in / Sign up

Export Citation Format

Share Document